Search En menu en ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages


    A boost for manufacture and access to COVID-19 vaccines in Africa

    An Africa COVID-19 vaccine production plant in Senegal is part of a plan to boost regional healthcare and to make the continent less reliant on imported vaccines.

    First signature
    EUR 4,750,000
    Regional - West Africa
    See more


    Amount (.*)
    € 4,750,000
    Regional - West Africa : € 4,750,000
    Industry : € 4,750,000
    Signature date(s)
    8/07/2021 : € 4,750,000
    (*) Including a € 4,750,000 Investment Grants provided by the EU-AFRICA INFRASTRUCTURE TRUST FUND

    News & Stories

    Link to source

    Inside the project

    How and Why

    Accessible health products and vaccines produced in Africa


    • Fewer than 2% of the three billion vaccine doses administered globally have been in Africa
    • New manufacturing facilities on the continent are essential, as Africa currently imports 99% of its vaccines
    • The COVID-19 pandemic highlighted the need to increase vaccination in Africa


    • The vaccine production facility at the Institut Pasteur de Dakar plans to produce as many as 25 million doses of an approved COVID-19 vaccine a month by the end of 2022
    • Improve investment in Africa’s health sector and boost the production and accessibility of heath products and technologies
    • Support technology transfer and the creation of regional vaccine manufacturing hubs in other regions of Africa


    A €1 billion package for Africa

    The European Investment Bank’s support for Institut Pasteur de Dakar is part of a €1 billion package of investment in vaccines, medicines and health technology in Africa that was launched at the G20 Global Health Summit in Rome May 2021.

    The COVID pandemic has highlighted the need to increase vaccination in Africa
    Dr Amadou Sall

    Director of the Institut Pasteur de Dakar



    A COVID-19 vaccine of its own for Africa

    If you want to stop the transmission or limit the severity of the disease, we need to vaccinate more people.
    Dr Amadou Sall

    Director of the Institut Pasteur de Dakar, which aims to raise Africa’s capacity to produce vaccines

    To increase vaccination rates, Africa needs to secure more doses. New manufacturing facilities on the continent are essential, as Africa currently imports 99% of its vaccines. The new vaccine production facility at the Institut Pasteur de Dakar is a key link in a vaccine strategy developed by the African Union and the Africa Centres for Disease Control and Prevention.

     “Not only does this reinforce the health system, but also through this particular project it will create jobs, develop capacities in terms of knowhow and workforce, while bringing in new technology,” says Sall.

    It’s very important that we have this solidarity between African countries and European countries because it helps to build up a global ecosystem for global health security.
    Amadou Sall

    Director of the Institut Pasteur de Dakar

    Africa is fully reliant on other countries to produce vaccines and make them available to African people
    Ramon Ynaraja

    The European Investment Bank’s representative in Senegal

    Costly and complicated process

    Vaccine manufacturing programmes are expensive and complex, even for sophisticated organisations like the Institut Pasteur de Dakar, which has over 80 years of experience developing vaccines and is currently the only facility in Africa producing a vaccine accepted by the World Health Organization.

    To kick-start development of the new facility, the EU bank, the European Commission, France and Germany, working together as Team Europe, provided grants, technical assistance and training. Another member of the team, Belgium, is working with Senegal on a plan to develop the country as a regional hub for pharmaceuticals, with the regional government of Wallonia also supporting a Belgian biotech company that will help the institute on capacity building and technology transfer. Other international partners, including the US and the World Bank Group, are also involved and will continue to support the project during the development phase, when the total cost could reach €100 million to €200 million.

    Learn more about what goes into coronavirus medical research and innovation:

    An investment in global heath security

    Europe’s support in Africa is also about global health care and making sure all countries can deal with the pandemic.

    “Many African countries, even those with the funds, simply cannot get access to vaccines on the market. This is why this site in Senegal, which will cover the entire production chain, is so important for the continent.” says Ramon Ynaraja, the European Investment Bank’s representative in Senegal.

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications